Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 5 clinical trials
Camrelizumab Combined With Apatinib Mesylate for Head and Neck Squamous Cell Carcinoma

This is a prospective, open-labelled study to evaluate the efficacy and safety of camrelizumab combined with apatinib mesylate in the induction treatment of patients with locally advanced head and neck squamous cell carcinoma who were judged surgically unresectable or appropriate for non-surgical definitive therapy.

squamous cell carcinoma of head and neck
apatinib
measurable disease
carcinoma
definitive treatment
  • 0 views
  • 19 Feb, 2024
  • 1 location
Neoadjuvant PD-1 Antibody Plus Apatinib or Chemotherapy for Non-small Cell Lung Cancer

The participants will receive neoadjuvant PD-1 inhibitor (camrelizumab) combined with antiangiogenic drug (apatinib) or platinum-based chemotherapy.

cancer immunotherapy
camrelizumab
measurable disease
kidney function test
blood transfusion
  • 0 views
  • 19 Feb, 2024
  • 1 location
Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL

This study will evaluate the efficacy and safety of camrelizumab in combination with apatinib in in patients with relapsed or refractory diffuse large B cell lymphoma failed from second line chemotherapy.

serum bilirubin
measurable disease
prothrombin time (pt)
blood transfusion
pulmonary function test
  • 0 views
  • 19 Feb, 2024
  • 1 location
Inductive Camrelizumab and Apatinib for Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma

The innovation of this study is the combination of immune checkpoint inhibitor, Camrelizumab, and targeted drug against VEGFR, Apatinib, as an inductive therapy to treat the patients with locally advanced OSCC, followed with radical surgery and post-operative radiotherapy/chemoradiotherapy, the major pathologic response and safety will be evaluated as the primary …

camrelizumab
hypoxia
carcinoma
growth factor
tumor burden
  • 0 views
  • 19 Feb, 2024
  • 1 location
Prediction of Therapeutic Response of Apatinib in Recurrent Gliomas

This study aims to collect clinical, radiological and histopathology imaging including detailed radiological data, survival data, clinical parameters, molecular pathology and images of HE slices in patients with recurrent gliomas whose are treated with Apatinib, for evaluating the efficacy and safety of Apatinib. Moreover, by leveraging artificial intelligence, this study …

glioma
vegf
platelet count
apatinib
postoperative complication
  • 0 views
  • 19 Feb, 2024
  • 1 location